The Use of Daptomycin for Staphylococcus Aureus Infections in Critical Care Medicine

Critical Care Clinics

Volumn 24, Issue 2, 2008, Pages 349-363

  Alder, Jeffrey ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOXACILLIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; LINEZOLID; NAFCILLIN; OXACILLIN; PENICILLIN G; VANCOMYCIN;

BACTEREMIA; BACTERIAL ENDOCARDITIS; CREATINE KINASE BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; FEVER; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NEPHROTOXICITY; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; RASH; RED MAN SYNDROME; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CRITICAL CARE; DAPTOMYCIN; GRAM-POSITIVE BACTERIA; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 40849085153     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.12.010     Document Type: Review

References (72)

1. Noskin G.A., Rubin R.J., Schentag J.J., et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample database. Arch Intern Med 165 (2005) 1756-1761
2. English B.K., Maryniw E.M., Talati A.J., et al. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob Agents Chemother 50 6 (2006) 2225-2227
3. Centers for Disease Control and Prevention. CDC website. MRSA in healthcare settings. Available at: http://www.cdc.gov/ncidod/dhqp/ar_MRSA_spotlight_2006.html. Accessed June 1, 2007.
4. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance System. CDC website. MRSA among ICU patients, 1995-2004. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/ICU_RESTrend1995-2004.pdf. Accessed June 1, 2007.
5. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317 [erratum, Clin Infect Dis 2004;39:1093]
6. Fowler Jr. V.G., Miro J.M., Hoen B., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005) 3012-3021 [erratum, JAMA 2005;294:900]
7. Miro J.M., Anguera I., Cabell C.H., et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41 (2005) 507-514 [erratum, Clin Infect Dis 2005;41:1075-7]
8. Fowler Jr. V.G., Olsen M.K., Corey G.R., et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163 (2003) 2066-2072
9. Fowler Jr. V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 7 (2006) 653-665
10. Fowler Jr. V.G., Sakoulas G., McIntyre L.M., et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 190 (2004) 1140-1149
11. Howden B.P., Ward P.B., Charles P.G.P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 4 (2004) 521-528
12. Charles P.G., Ward P.B., Johnson P.D., et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
13. Kirst H.A., Thompson D.G., and Nicas T.I. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 42 5 (1998) 1303-1304
14. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States 2002. MMWR Morb Mortal Wkly Rep 51 26 (2002) 565-567
15. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1 3 (2001) 147-155
16. Moore M.R., Perdreau-Remington F., and Chambers H.F. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47 4 (2003) 1262-1266
17. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 1 (2003) 53-59
18. Whitby M., McLaws M.L., and Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis. Med J Aust 175 5 (2001) 264-267
19. Chambers H.F., Miller R.T., and Newman M.D. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 109 8 (1988) 619-624
20. Chang F.Y., MacDonald B.B., Peacock Jr. J.E., et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82 (2003) 322-332
21. Chang F.Y., Peacock Jr. J.E., Musher D.M., et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82 5 (2003) 333-339
22. Small P.M., and Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34 6 (1990) 1227-1231
23. Tedesco K.L., and Rybak M.J. Daptomycin. Pharmacotherapy 24 1 (2004) 41-57
24. Tenover F.C., Lancaster M.V., Hill B.C., et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 36 4 (1998) 1020-1027
25. Trucksis M., Hooper D.C., and Wolfson J.S. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 114 5 (1991) 424-426
26. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115 9 (1991) 674-680
27. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166 (2006) 2138-2144
28. Farber B.F., and Moellering Jr. R.C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23 1 (1983) 138-141
29. Rocha J.L.L., Kondo W., Baptista M.I.D.K., et al. Uncommon vancomycin-induced side effects. Braz J Infect Dis 6 4 (2002) 196-200
30. Darko W., Medicis J.J., Smith A., et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 23 5 (2003) 643-650
31. Von Drygalski A., Curtis B.R., Bougie D.W., et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 356 9 (2007) 904-910
32. Weigelt J., Itani K., Stevens D., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
33. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
34. Lawrence K.R., Adra M., and Gillman P.K. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 42 (2006) 1578-1583
35. Perry C.M., and Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 61 (2001) 525-551
36. Wu V.C., Wang Y.T., Wang C.Y., et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 42 (2006) 66-72
37. Sader H., Fritsche T., and Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 50 7 (2006) 2330-2336
38. Lakey J.H., and Ptak M. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry 27 13 (1988) 4639-4645
39. Silverman J.A., Perlmutter N.G., and Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47 8 (2003) 2538-2544
40. Eisenstein B.I. Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections. Expert Opin Investig Drugs 13 9 (2004) 1159-1169
41. Mortin L.I., Li T., Van Praagh A.D., et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 51 5 (2007) 1787-1794
42. ® (daptomycin for injection) package insert (2007), Cubist Pharmaceuticals, Inc., Lexington (MA)
43. Arbeit R.D., Maki D., Tally F.P., et al., Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 12 (2004) 1673-1681
44. Kvirikadze N., Suseno M., Vescio T., et al. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 38 4 (2006) 290-292
45. Mohan S.S., McDermott B.P., and Cunha B.A. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 34 1 (2005) 69-71
46. Segreti J.A., Crank C.W., and Finney M.S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26 3 (2006) 347-352
47. Falagas M.E., Giannopoulou K.P., Ntziora F., et al. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60 1 (2007) 7-19
48. Rehm SJ, Boucher HW, Campion M, et al. Community-based parenteral antimicrobial therapy for patients with Staphylococcus aureus bacteremia (SAB) or infective endocarditis (SAIE). Infectious Diseases Society America 2007 Annual Conference. Poster # 265.
49. Dholakia H, Kapila R, Burday M, et al. Daptomycin for the treatment of left-sided endocarditis: a case series. Infectious Diseases Society America 2007 Annual Conference. Poster # 1103.
50. Sakoulas G, Forest G, Brown J, et al. Daptomycin (DAP) for the treatment of community-associated methicillin-resistant Staphylococcus aureus phenotype (CPMRSA) bacteremia. Infectious Diseases Society America 2007 Annual Conference. Poster # 253.
51. Finney M.S., Crank C.W., and Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin 21 12 (2005) 1923-1926
52. Burns C.A. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 38 2 (2006) 133-136
53. Antony SJ, Tiscareno-Grejeda I. Use of daptomycin in the treatment of prosthetic joint infections. Infectious Diseases Society America 2007 Annual Conference. Poster # 1091.
54. Lamp KC, Donovan B. Experience with daptomycin for community-associated methicillin-resistant Staphylococcus aureus phenotype (CPMRSA) osteomyelitis. Infectious Diseases Society America 2007 Annual Conference. Poster # 255.
55. Rouse M.S., Piper K.E., Jacobson M., et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 57 2 (2006) 301-305
56. Cunha B.A., Hamid N., Kessler H., et al. Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung 34 6 (2005) 442-447
57. Cunha B.A., Eisenstein L.E., and Hamid N.S. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 35 3 (2006) 207-211
58. Silverman J.A., Mortin L.I., Vanpraagh A.D.G., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
59. Gerber P., Stucki A., Acosta F., et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 57 4 (2006) 720-723
60. Cottagnoud P., Pfister M., Acosta F., et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 48 10 (2004) 3928-3933
61. Finberg R.W., Moellering R.C., Tally F.P., et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 39 9 (2004) 1314-1320
62. Herzstein J., Ryan J.L., Mangi R.J., et al. Optimal therapy for enterococcal endocarditis. Am J Med 76 2 (1984) 186-191
63. Jawetz E., Gunnison J.B., and Coleman V.R. Combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro. Am J Med 8 4 (1950) 532
64. Weinstein A.J., and Moellering Jr. R.C. Penicillin and gentamicin therapy for enterococcal infections. JAMA 223 9 (1973) 1030-1032
65. Lepper M.H., and Dowling H.F. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. AMA Arch Intern Med 88 4 (1951) 489-494
66. Mathies Jr. A.W., Leedom J.M., Ivler D., et al. Antibiotic antagonism in bacterial meningitis. Antimicrobial Agents Chemother (Bethesda) 7 (1967) 218-224
67. Dickie A.S. Current concepts in the management of infections in bones and joints. Drugs 32 5 (1986) 458-475
68. Wale L.J., Shelton A.P., and Greenwood D. Scanning electron microscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin. J Med Microbiol 30 1 (1989) 45-49
69. Grandgirard D., Schurch C., Cottagnoud P., et al. Prevention of brain injury by the non bacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 51 6 (2007) 2173-2178
70. Nau R., and Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15 1 (2002) 95-110
71. Di Filippo A., and De Gaudio A.R. Device-related infections in critically ill patients. Part II: prevention of ventilator-associated pneumonia and urinary tract infections. J Chemother 15 6 (2003) 536-542
72. Wiederhold N.P., Coyle E.A., Raad I.I., et al. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia. J Antimicrob Chemother 55 5 (2005) 792-795